Clinical Research Directory
Browse clinical research sites, groups, and studies.
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
Sponsor: Sclnow Biotechnology Co., Ltd.
Summary
The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.
Official title: A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia
Key Details
Gender
All
Age Range
16 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2025-12-31
Completion Date
2026-12-31
Last Updated
2025-12-04
Healthy Volunteers
No
Conditions
Interventions
Intravenous infusion
Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)
Intrathecal injection
Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)
umbilical cord mesenchymal stem cell
Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure